Catalent launches $500 million term loan B-4 at SOFR plus 300-325 bps

By Sara Rosenberg

New York, Dec. 11 – Catalent Pharma Solutions Inc. was scheduled to hold a lender call at 11 a.m. ET on Monday to launch a $500 million incremental term loan B-4 due 2028 (BB-) that is talked at SOFR plus 300 basis points to 325 bps with a 0.5% floor and an original issue discount of 98.5, according to a market source.

The incremental term loan has 101 soft call protection for six months and 50 bps MFN for 12 months, the source said.

JPMorgan Chase Bank is the lead on the deal.

Proceeds will be used to repay revolving credit facility borrowings.

Catalent is a Somerset, N.J.-based provider of development sciences and manufacturing platforms for medicines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.